Literature DB >> 31214702

Columnar Injection for Intracerebral Cell Therapy.

Jeffrey S Schweitzer1,2, Bin Song3,4, Pierre R Leblanc3,4, Melissa Feitosa3,4, Bob S Carter1,2, Kwang-Soo Kim3,4.   

Abstract

BACKGROUND: Surgical implantation of cellular grafts into the brain is of increasing importance, as stem cell-based therapies for Parkinson and other diseases continue to develop. The effect of grafting technique on development and survival of the graft has received less attention. Rate and method of graft delivery may impact the cell viability and success of these therapies. Understanding the final location of the graft with respect to the intended target location is also critical.
OBJECTIVE: To describe a "columnar injection" technique designed to reduce damage to host tissue and result in a column of graft material with greater surface area to volume ratio than traditional injection techniques.
METHODS: Using a clinically relevant model system of human embryonic stem cell-derived dopaminergic progenitors injected into athymic rat host brain, we describe a novel device that allows separate control of syringe barrel and plunger, permitting precise deposition of the contents into the cannula tract during withdrawal. Controls consist of contralateral injection using traditional techniques. Graft histology was examined at graft maturity.
RESULTS: Bolus grafts were centered on the injection tract but were largely proximal to the "target" location. These grafts displayed a conspicuous peripheral distribution of cells, particularly of mature dopaminergic neurons. In contrast, column injections remained centered at the intended target, contained more evenly distributed cells, and had significantly more mature dopaminergic neurons.
CONCLUSION: We suggest that this columnar injection technique may allow better engraftment and development of intracerebral grafts, enhancing outcomes of cell therapy, compared to fixed-point injection techniques.
Copyright © 2019 by the Congress of Neurological Surgeons.

Entities:  

Keywords:  Cell therapy; Dopaminergic neurons; Stereotaxy

Mesh:

Substances:

Year:  2020        PMID: 31214702      PMCID: PMC7311830          DOI: 10.1093/ons/opz143

Source DB:  PubMed          Journal:  Oper Neurosurg (Hagerstown)        ISSN: 2332-4252            Impact factor:   2.703


  35 in total

Review 1.  Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.

Authors:  Kai-C Sonntag; Bin Song; Nayeon Lee; Jin Hyuk Jung; Young Cha; Pierre Leblanc; Carolyn Neff; Sek Won Kong; Bob S Carter; Jeffrey Schweitzer; Kwang-Soo Kim
Journal:  Prog Neurobiol       Date:  2018-04-11       Impact factor: 11.685

2.  Fetal grafts for Parkinson's disease: Decades in the making.

Authors:  Jeffrey H Kordower; C Warren Olanow
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-31       Impact factor: 11.205

3.  Both apoptosis and necrosis occur early after intracerebral grafting of ventral mesencephalic tissue: a role for protease activation.

Authors:  M Emgård; U Hallin; J Karlsson; B A Bahr; P Brundin; K Blomgren
Journal:  J Neurochem       Date:  2003-09       Impact factor: 5.372

4.  Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease.

Authors:  D E Redmond; A Vinuela; J H Kordower; O Isacson
Journal:  Neurobiol Dis       Date:  2007-08-28       Impact factor: 5.996

5.  Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain.

Authors:  Wen Li; Elisabet Englund; Håkan Widner; Bengt Mattsson; Danielle van Westen; Jimmy Lätt; Stig Rehncrona; Patrik Brundin; Anders Björklund; Olle Lindvall; Jia-Yi Li
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-02       Impact factor: 11.205

6.  Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease.

Authors:  T B Freeman; C W Olanow; R A Hauser; G M Nauert; D A Smith; C V Borlongan; P R Sanberg; D A Holt; J H Kordower; F J Vingerhoets
Journal:  Ann Neurol       Date:  1995-09       Impact factor: 10.422

7.  Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years.

Authors:  Ivar Mendez; Angel Viñuela; Arnar Astradsson; Karim Mukhida; Penelope Hallett; Harold Robertson; Travis Tierney; Renn Holness; Alain Dagher; John Q Trojanowski; Ole Isacson
Journal:  Nat Med       Date:  2008-04-06       Impact factor: 53.440

8.  A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.

Authors:  C Warren Olanow; Christopher G Goetz; Jeffrey H Kordower; A Jon Stoessl; Vesna Sossi; Mitchell F Brin; Kathleen M Shannon; G Michael Nauert; Daniel P Perl; James Godbold; Thomas B Freeman
Journal:  Ann Neurol       Date:  2003-09       Impact factor: 10.422

Review 9.  Survival, differentiation, and connectivity of ventral mesencephalic dopamine neurons following transplantation.

Authors:  Lachlan Thompson; Anders Björklund
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

10.  Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research.

Authors:  Carol Kilkenny; William J Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  J Pharmacol Pharmacother       Date:  2010-07
View more
  2 in total

1.  Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease.

Authors:  Jeffrey S Schweitzer; Bin Song; Todd M Herrington; Tae-Yoon Park; Nayeon Lee; Sanghyeok Ko; Jeha Jeon; Young Cha; Kyungsang Kim; Quanzheng Li; Claire Henchcliffe; Michael Kaplitt; Carolyn Neff; Otto Rapalino; Hyemyung Seo; In-Hee Lee; Jisun Kim; Taewoo Kim; Gregory A Petsko; Jerome Ritz; Bruce M Cohen; Sek-Won Kong; Pierre Leblanc; Bob S Carter; Kwang-Soo Kim
Journal:  N Engl J Med       Date:  2020-05-14       Impact factor: 91.245

2.  Injectable Glycosaminoglycan-Based Cryogels from Well-Defined Microscale Templates for Local Growth Factor Delivery.

Authors:  Ben Newland; Heike Newland; Francesca Lorenzi; Dimitri Eigel; Petra B Welzel; Dieter Fischer; Wenxin Wang; Uwe Freudenberg; Anne Rosser; Carsten Werner
Journal:  ACS Chem Neurosci       Date:  2021-03-23       Impact factor: 4.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.